Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02125318
Other study ID # GALE-401-201
Secondary ID
Status Completed
Phase Phase 2
First received April 23, 2014
Last updated February 23, 2017
Start date May 2014
Est. completion date May 2016

Study information

Verified date February 2017
Source Galena Biopharma, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Anagrelide is a drug that has been shown to slow down how fast platelets are made in the bone marrow, and has been approved by the FDA for treating high platelets counts in patients with bone marrow disorders.

Anagrelide Controlled Release ("CR") is a new preparation of anagrelide that is made to dissolve more slowly than currently marketed versions of this drug. Because of this, the anagrelide is taken up into the blood more slowly. Researchers think that this slower release of the drug could help to lower side effects that might be caused by high blood levels when the drug dissolves as quickly as it does with the currently marketed product.

The main purposes of this study are to see how well Anagrelide CR can control platelet counts in patients with high platelet levels, to see what kind of side effects it causes, and to measure blood levels of the drug.


Description:

This is an open-label, single-arm, multicenter, Phase 2 study of anagrelide CR in subjects with an MPN-related thrombocytosis. Eligible subjects will include those who have not been previously treated for thrombocytosis or have not received platelet-lowering therapy for at least 2 weeks prior to study treatment. Each subject will receive anagrelide CR at a starting dose of 0.5 mg b.i.d. (1.0 mg/day), and is anticipated to continue study treatment for at least 24 weeks. Subjects who have achieved clinical benefit in the opinion of the Investigator and who are tolerating the study drug may continue study treatment until they develop unacceptable toxicity or other discontinuation criteria have been met.

The primary efficacy endpoint will be the proportion of subjects who achieve a platelet response (CR or PR). The safety and tolerability of study treatment will be assessed by the frequency and severity of adverse events as determined by NCI Common Terminology Criteria for Adverse Events (CTCAE) v 4.03. The PK profile of anagrelide CR will be assessed at the initial (0.5mg b.i.d.) and final titrated dose levels.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date May 2016
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Provide written informed consent prior to any study specific procedure

2. Male or female patients aged = 18 years

3. Diagnosis of a myeloproliferative neoplasm (i.e., chronic myelogenous leukemia (CML), polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET)) as determined by the treating physician, such as based on the 2008 World Health Organization (WHO) classification of myeloid malignancies

4. Baseline platelet count =600 x 10e9/L as determined on two occasions at least 14 days apart prior to the first dose of study drug

5. Requirement for platelet reduction therapy as assessed by the Investigator

6. Currently not receiving therapy specifically intended to reduce platelet counts

7. For patients with ET, prior platelet lowering therapy (e.g., hydroxyurea, anagrelide or interferon) may not be administered within 2 weeks prior to the first dose of study drug.

For patients with MPN diagnoses other than ET, concurrent anti-MPN treatment is permitted provided that the treatment has been administered at stable doses for at least 4 weeks prior to the first dose of study drug. Examples of permitted medications include but are not limited to hydroxyurea for PV, ruxolitinib for MF, and imatinib for CML. All patients must have discontinued anagrelide at least 2 weeks prior to the first dose of study drug.

EXCEPTION: busulfan, melphalan and phosphate P-32 must have been discontinued at least 4 weeks prior to the first dose of study drug.

8. Adequate hepatic function defined as bilirubin =1.5 x ULN, INR =1.5 x ULN, albumin >3.5 g/dL, ALT < 3.0 x ULN, AST < 3.0 x ULN

9. If female, must be of non-childbearing potential, i.e. post- menopausal (defined as > 12 months since last menstrual period) or surgically sterilized (i.e. tubal ligation or hysterectomy at least 6 months prior to screening) or, if of childbearing potential, must not be pregnant or nursing

10. Males and females of child bearing must agree to use an acceptable form of birth control until 28 days following the last dose of study drug

Exclusion Criteria:

1. Other MPN diagnoses not specifically included above: Chronic neutrophilic leukemia, chronic eosinophilic leukemia, mastocytosis, and unclassifiable MPNs

2. Previously found to be refractory to anagrelide therapy (i.e., failure to achieve a platelet count <600 x 10e9/L for reasons other than anagrelide-related toxicity)

3. History of coronary artery disease requiring a revascularization procedure within 3 months prior to screening

4. Left bundle branch block or sustained ventricular tachycardia (>30 seconds) evident on 12-lead ECG at screening

5. Tachycardia defined as resting heart rate >100 bpm at screening

6. Unstable angina (characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, or prolonged duration) within 3 months prior to screening

7. Transient ischemic attack (TIA) or stroke within 3 months prior to screening

8. Unstable or clinically significant concurrent medical condition that would, in the opinion of the Investigator, jeopardize the safety of a subject and/or their compliance with the protocol.

9. Current alcohol or drug abuse, or a significant medical condition that, in the opinion of the Investigator, may impair compliance with the requirements of the protocol

10. History of allergic hypersensitivity to anagrelide or any component of its formulations

11. Administration of Type 3 phosphodiesterase (PDE3) inhibitors (e.g., inamrinone, cilostazol, milrinone) within 2 weeks prior to initiating study treatment

12. Administration of any investigational product within 4 weeks prior to initiating study treatment

13. History of intolerance of other PDE3 inhibitors

Study Design


Intervention

Drug:
Anagrelide CR
Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.

Locations

Country Name City State
United States Innovative Medical Research of South Florida, Inc. Aventura Florida
United States East Valley Hematology and Oncology Medical Group Burbank California
United States California Cancer Associates for Research & Excellence (cCARE) Encinitas California
United States California Cancer Associates for Research & Excellence (cCARE) Escondido California
United States California Cancer Associates For Research and Excellence Fresno California
United States Gettysburg Cancer Center Gettysburgh Pennsylvania
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States Cancer Care Centers of South Texas New Braunfels Texas
United States Cancer Care Centers of South Texas San Antonio Texas
United States Cancer Center of Kansas Wichita Kansas
United States Wake Forest Baptist Health Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Galena Biopharma, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Platelet Response The primary efficacy endpoint will be the proportion of subjects who achieve a platelet response (complete or partial response), with response defined according to the following criteria:
Complete response (CR): platelet count of =400 x 10e9/L maintained for at least 4 weeks
Partial response (PR): a platelet count of =600 x 10e9/L or a =50% reduction from baseline and maintenance of the reduction for at least 4 weeks
Nonresponse: failure to meet CR or PR criteria
Up to 24 weeks
Secondary Number of subjects with adverse events Frequency and severity of adverse events as determined by NCI CTCAE (v 4.03). Throughout study treatment (expected average of 12 months)
Secondary Plasma concentrations of anagrelide Monitor anagrelide levels during dose titration and assess pharmacokinetic profile at starting and final dose levels. Up to 13 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Recruiting NCT05936359 - A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms Phase 1
Completed NCT02084563 - Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms Phase 2
Recruiting NCT04339400 - A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms Phase 1
Not yet recruiting NCT06291987 - Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation Phase 1
Recruiting NCT03314974 - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Phase 2
Completed NCT03075826 - A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms Phase 2
Recruiting NCT02823210 - Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders
Not yet recruiting NCT06313593 - A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms Phase 1
Recruiting NCT05444530 - A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms Phase 1
Recruiting NCT03912064 - A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Phase 1
Terminated NCT02393248 - Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Phase 1/Phase 2
Completed NCT02076191 - Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Phase 1/Phase 2
Active, not recruiting NCT04761770 - Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders Phase 2
Recruiting NCT06034002 - A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms Phase 1
Completed NCT00949364 - Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Phase 2
Completed NCT00053196 - Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Phase 2
Terminated NCT01668173 - HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET Phase 2
Active, not recruiting NCT03618485 - Registry of Patients With MPNs in Taiwan